Three Biotechs That Takeover: Top 2026 M&A Targets
As large pharma hunts for GLP-1 and cardiovascular assets, three biotechs stand out as hot takeover targets. This rep...
Compare 2024 dividend aristocrats ETF fees to find the lowest cost option. This guide highlights expense ratios and what to look for in a low-cost fund.
27,654 articlesAs large pharma hunts for GLP-1 and cardiovascular assets, three biotechs stand out as hot takeover targets. This rep...
U.S. stocks surged, with the S&P 500 hitting a fresh peak and a new company joining the $1 trillion market-cap circle...
Lululemon faces a pivotal moment after its latest earnings. This analysis breaks down what's working, what's slowing,...
New annual reports warn that the social security medicare heading toward insolvency, setting up a high-stakes debate ...
A New York-based AI startup led by a 21-year-old cofounder pitches clients with a provocative call to skepticism. The...
Goldman’s Lindsay Rosner says July rate hikes are on the table as inflation and energy prices keep Fed expectations a...
Goldman Sachs warns that leveraged stock bets are extremely focused on AI stocks, creating risk if AI sentiment shift...
Artificial intelligence is remaking markets. This guide explains why leaders Nvidia, Palantir, and Meta matter for in...
Ethereum hovers around $1,800 as thin volume and mixed social signals keep the market gridlocked. A tweet-driven mome...
Tesla faces a pivotal Q2 print as shares struggle in 2026. While deliveries rose, investors will be watching margins,...
BluePeak Capital disclosed it sold additional common shares to fund a $40 million bitcoin purchase, even as its total...
A growing cohort of workers is quietly stacking multiple full-time roles, pushing total earnings into six figures and...